Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study
European Journal of Nuclear Medicine and Molecular Imaging · 2025-09 · 52 (11) · 4001-4015
DOI: 10.1007/s00259-025-07246-7 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 08.04.2025. Verfasst von Mark N Gaze und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Adrenal Gland Neoplasms, Intestinal Neoplasms, Neuroendocrine Tumors, Octreotide. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Advanced Accelerator Applications, a Novartis Company.
Abstract (Originalsprache)
PURPOSE: NETTER-P, an open-label Phase II study, evaluated the safety and dosimetry of [177Lu]Lu-DOTA-TATE (hereafter 177Lu-DOTATATE) in adolescents with advanced, somatostatin receptor-positive, well-differentiated, Grade 1/2 gastroenteropancreatic neuroendocrine tumours (GEP-NET) or pheochromocytoma and paragangliomas (PPGL). METHODS: Patients (12-17 years old) received four cycles of 177Lu-DOTATATE (7.4 GBq every 8 ± 1 weeks; cumulative administered activity: 29.6 GBq). Primary endpoints were absorbed dose (kidneys and bone marrow) and safety after first administration. Safety during treatment and comparative assessments of dosimetry and pharmacokinetics between adolescents and historical adult patients were evaluated. RESULTS: Eleven patients (4 GEP-NET, 7 PPGL; median age 15 [range, 13-17] years) were enrolled and received ≥ 1 administration of 177Lu-DOTATATE. Median (range) cumulative administered activity was 28.2 (7.3-29.9) GBq. Lymphopenia/lymphocyte count decreased and headache were the most common adverse events (AEs) during Cycle 1 (each 4/11 [36%]). Cycle 1 Grade ≥ 3 AEs occurred in 4/11 patients (36%). During the treatment period, the most common AE was lymphopenia/lymphocyte count decreased (7/11 [64%]; Grade ≥ 3, 5/11 [45%]). No clinically meaningful impacts on safety biomarkers nor any treatment-related nephrotoxicities were observed. Projected median (range) cumulative absorbed doses (four administrations) were 21 (14-40) Gy in kidneys and 0.76 (0.55-1.0) Gy in bone marrow (using blood data). Dosimetry values were predicted to be within safety thresholds for adolescents and adults; pharmacokinetics were comparable in both populations. CONCLUSION: No new safety signals attributable to 177Lu-DOTATATE were identified in adolescents with GEP-NET or PPGL versus adults with GEP-NET. Long-term follow-up is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04711135. Registered 15 January 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
- Maria Skłodowska-Curie Memorial National Research Institute of Oncology, Gliwice, Poland.
- Hospital Vall d'Hebrón, Barcelona, Spain.
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
- University of Kentucky, Lexington, KY, USA.
- CDE Dosimetry Services Inc, Knoxville, TN, USA.
ORCID-Profile: Mark N Gaze, Daria Handkiewicz-Junak, Theodore W Laetsch, Simon Wan, Antony Ceraulo, Cristina Gámez-Cenzano, Lisa J States, Gabor Kollar, Anne-Laure Giraudet
Förderung
- Advanced Accelerator Applications, a Novartis Company
Zitieren
APA
Gaze, M. N., Handkiewicz-Junak, D., Hladun, R., Laetsch, T. W., Sorge, C., Sparks, R., Wan, S., Ceraulo, A., Kluczewska-Galka, A., Gámez-Cenzano, C., States, L. J., El Khouli, R., Aimone, P., Perraud, K., Kollar, G., Khanshan, F., Blumenstein, L., Brouri, F., & Giraudet, A. L. (2025). Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. European Journal of Nuclear Medicine and Molecular Imaging, 52(11), 4001-4015. https://doi.org/10.1007/s00259-025-07246-7
Vancouver
Gaze MN, Handkiewicz-Junak D, Hladun R, Laetsch TW, Sorge C, Sparks R, et al. Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(11):4001-4015. doi:10.1007/s00259-025-07246-7
BibTeX
@article{Gaze2025,
author = {Gaze, Mark N and Handkiewicz-Junak, Daria and Hladun, Raquel and Laetsch, Theodore W and Sorge, Caryn and Sparks, Richard and Wan, Simon and Ceraulo, Antony and Kluczewska-Galka, Aneta and Gámez-Cenzano, Cristina and States, Lisa J and El Khouli, Riham and Aimone, Paola and Perraud, Kevin and Kollar, Gabor and Khanshan, Fariba and Blumenstein, Lars and Brouri, Fazia and Giraudet, Anne-Laure},
title = {Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {11},
pages = {4001--4015},
doi = {10.1007/s00259-025-07246-7}
}
EUVIMED